BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer
Summary
USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.
What changed
USPTO issued patent grant US12595289B2 to Tokushima University for a novel therapeutic agent comprising a BIG3-PHB2 interaction-inhibiting peptide. The invention provides pharmaceutical compositions containing the peptide for treating breast cancer, specifically targeting estrogen receptor-positive cancers. The peptide binds to BIG3 protein (highly expressed in certain cancer cells) rather than PHB2, offering growth suppressive effects on BIG3-positive cancer cells.
For pharmaceutical manufacturers and researchers developing cancer therapeutics, this patent establishes intellectual property protection for peptide-based cancer treatments targeting the BIG3-PHB2 pathway. Companies engaged in oncology drug development should consider freedom-to-operate analyses and potential licensing needs when developing competing or complementary therapeutic approaches in this space.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Therapeutic agent for breast cancer comprising BIG3-PHB2 interaction-inhibiting peptide derived from PHB2
Grant US12595289B2 Kind: B2 Apr 07, 2026
Assignee
TOKUSHIMA UNIVERSITY
Inventors
Toyomasa Katagiri, Tetsuro Yoshimaru, Akira Otaka, Takashi Miyamoto, Yasuhide Okamoto
Abstract
The present invention provides peptides containing the BIG3 polypeptide-binding site in a PHB2 polypeptide, which inhibit the binding between a PHB2 polypeptide and a BIG3 polypeptide, and pharmaceutical compositions containing the peptide. The peptides of the present invention have the ability to bind not to PHB2, whose expression is found in organs throughout the human body, but to BIG3, which is a protein highly expressed specifically in particularly estrogen receptor-positive cancer, and have excellent growth suppressive effects on BIG3-positive cancer cells. Accordingly, the peptides of the present invention are useful as therapeutic agents for breast cancer which can avoid expression of side effects.
CPC Classifications
C07K 14/4703 C07K 14/4748 C07K 19/00 A61P 35/00 A61P 43/00 A61K 38/00
Filing Date
2019-11-28
Application No.
17297986
Claims
6
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.